ATE346303T1 - Mit alzheimer krankheit verknüpften verfahren zur diagnose, zur herstellung von medikamenten und zum screenen von substanzen sowie aus beta- amyloid abgeleiteten peptiden - Google Patents

Mit alzheimer krankheit verknüpften verfahren zur diagnose, zur herstellung von medikamenten und zum screenen von substanzen sowie aus beta- amyloid abgeleiteten peptiden

Info

Publication number
ATE346303T1
ATE346303T1 AT97919932T AT97919932T ATE346303T1 AT E346303 T1 ATE346303 T1 AT E346303T1 AT 97919932 T AT97919932 T AT 97919932T AT 97919932 T AT97919932 T AT 97919932T AT E346303 T1 ATE346303 T1 AT E346303T1
Authority
AT
Austria
Prior art keywords
disease
methods
alzheimer
beta
medications
Prior art date
Application number
AT97919932T
Other languages
German (de)
English (en)
Inventor
Barbara A Gilchrest
Mina Yaar
Original Assignee
Univ Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Boston filed Critical Univ Boston
Application granted granted Critical
Publication of ATE346303T1 publication Critical patent/ATE346303T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
AT97919932T 1996-03-29 1997-03-28 Mit alzheimer krankheit verknüpften verfahren zur diagnose, zur herstellung von medikamenten und zum screenen von substanzen sowie aus beta- amyloid abgeleiteten peptiden ATE346303T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62576596A 1996-03-29 1996-03-29

Publications (1)

Publication Number Publication Date
ATE346303T1 true ATE346303T1 (de) 2006-12-15

Family

ID=24507498

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97919932T ATE346303T1 (de) 1996-03-29 1997-03-28 Mit alzheimer krankheit verknüpften verfahren zur diagnose, zur herstellung von medikamenten und zum screenen von substanzen sowie aus beta- amyloid abgeleiteten peptiden

Country Status (8)

Country Link
US (3) US6242416B1 (Direct)
EP (1) EP0890105B1 (Direct)
JP (1) JP2000507828A (Direct)
AT (1) ATE346303T1 (Direct)
AU (1) AU719038B2 (Direct)
CA (1) CA2250075C (Direct)
DE (1) DE69736976T2 (Direct)
WO (1) WO1997037228A1 (Direct)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867179B1 (en) 1994-08-31 2005-03-15 Trustees Of Boston University Methods of inducing hair growth and coloration
US7196055B2 (en) 1994-08-31 2007-03-27 Trustees Of Boston University Inhibition of apoptosis in keratinocytes by a ligand of p75 nerve growth factor receptor
JP2000507828A (ja) 1996-03-29 2000-06-27 ザ トラスティーズ オブ ボストン ユニバーシティー アルツハイマー病の診断および治療法
US6258932B1 (en) * 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
IL147970A0 (en) * 1999-08-09 2002-09-12 Tripep Ab Pharmaceutical compositions containing tripeptides
KR20020007432A (ko) * 2000-07-13 2002-01-29 박현석 멜라노트랜스페린에 대한 단클론 항체를 유효성분으로포함하는 알츠하이머병의 진단시약
US6593455B2 (en) * 2001-08-24 2003-07-15 Tripep Ab Tripeptide amides that block viral infectivity and methods of use thereof
US6455670B1 (en) * 2001-09-06 2002-09-24 Tripep Ab Pentamer peptide amide, ALGPG-NH2, that inhibits viral infectivity and methods of use thereof
EP1436317A1 (en) * 2001-09-19 2004-07-14 Tripep Ab Molecules that block viral infectivity and methods of use thereof
AUPS230702A0 (en) * 2002-05-14 2002-06-13 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
US20050096319A1 (en) * 2003-02-21 2005-05-05 Balzarini Jan M.R. Identification of compounds that inhibit replication of human immunodeficiency virus
US20040180893A1 (en) * 2003-02-21 2004-09-16 Balzarini Jan Maria Rene Identification of compounds that inhibit replication of human immunodeficiency virus
WO2004087744A2 (en) * 2003-03-28 2004-10-14 Intellectual Property Consulting Inc. Composition and method for nerve regeneration
CA2525476C (en) * 2003-05-08 2013-07-30 Pentapharm Ag Tripeptides and derivatives thereof for cosmetic application in order to improve skin structure
WO2005122712A2 (en) * 2003-06-11 2005-12-29 Socratech L.L.C. Soluble low-density lipoprotein receptor related protein binds directly to alzheimer’s amyloid-beta peptide
EP1500399A1 (en) * 2003-07-24 2005-01-26 Institut Pasteur Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases
US20110230479A1 (en) * 2005-04-15 2011-09-22 Longo Frank M Neurotrophin mimetics and uses thereof
EP2586445A1 (en) * 2005-04-15 2013-05-01 University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
US8110672B2 (en) * 2005-04-27 2012-02-07 Massachusetts Institute Of Technology Promoter engineering and genetic control
CA2667260A1 (en) * 2006-10-23 2008-05-02 National University Corporation Nagoya University Intracerebral oxidation inhibitor and use thereof
AU2009319864A1 (en) 2008-11-25 2011-07-14 Biogen Idec Ma Inc. Use of DR6 and P75 antagonists to promote survival of cells of the nervous system
TW201034684A (en) * 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
US9458427B2 (en) * 2009-08-07 2016-10-04 Case Western Reserve University IFNγR2 compositions and methods of inhibiting neuronal cell death
KR20120103587A (ko) * 2009-11-12 2012-09-19 제넨테크, 인크. 수상돌기 소극 밀도를 증진시키는 방법
EP3470402B1 (en) 2009-11-12 2021-01-06 Pharmatrophix Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
SG183854A1 (en) 2010-03-03 2012-10-30 Univ British Columbia Oligomer-specific amyloid beta epitope and antibodies
AU2013205000B2 (en) * 2010-03-03 2015-05-28 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies
DK2646462T3 (en) 2010-11-29 2017-07-03 Akershus Univ METHODS AND COMPOSITIONS FOR MONITORING PHAGOCYTIC ACTIVITY
WO2013052922A1 (en) * 2011-10-05 2013-04-11 Blanchette Rockefeller Neurosciences Institute Stimulus-elicited genomic profile markers of a neurodegenerative condition
US9534016B2 (en) * 2011-11-28 2017-01-03 Buck Institute For Research On Aging Netrin loop peptide mimetics and uses thereof
GB2516045A (en) * 2013-07-09 2015-01-14 Neuro Bio Ltd Neurodegenerative disorders
ES2699410T3 (es) * 2014-05-28 2019-02-11 Univ Dresden Tech Ensayo basado en células y métodos de cribado de moduladores de la señalización de p75NTR
KR102732610B1 (ko) * 2017-03-06 2024-11-21 니폰 조키 세야쿠 가부시키가이샤 Aβ-유발 손상에 대한 신경 보호능을 측정하는 방법
JP6359160B2 (ja) * 2017-07-25 2018-07-18 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
CN119661638B (zh) * 2024-11-22 2025-07-18 象山县第一人民医院医疗健康集团(宁波市第四医院、宁波市第四医院医院管理研究所) 一种修复神经损伤的多肽、制备方法及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4918405A (en) * 1988-10-26 1990-04-17 Hewlett-Packard Company Signal generator utilizing a combined phase locked and frequency locked loop
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
IL101661A (en) * 1991-04-23 1998-02-08 Regeneron Pharma Method for detecting, identifying or measuring agents having neurotrophin activity
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
US5976816A (en) 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
GB9402331D0 (en) * 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
US5576209A (en) * 1994-10-24 1996-11-19 The Regents Of The University Of California Method for increasing the resistance of neural cells to β-amyloid peptide toxicity
JP2000507828A (ja) * 1996-03-29 2000-06-27 ザ トラスティーズ オブ ボストン ユニバーシティー アルツハイマー病の診断および治療法

Also Published As

Publication number Publication date
EP0890105B1 (en) 2006-11-22
AU719038B2 (en) 2000-05-04
US6696303B2 (en) 2004-02-24
CA2250075C (en) 2008-06-10
US20040254110A1 (en) 2004-12-16
JP2000507828A (ja) 2000-06-27
WO1997037228A1 (en) 1997-10-09
US6242416B1 (en) 2001-06-05
CA2250075A1 (en) 1997-10-09
DE69736976D1 (de) 2007-01-04
AU2424597A (en) 1997-10-22
US20020051988A1 (en) 2002-05-02
EP0890105A1 (en) 1999-01-13
DE69736976T2 (de) 2007-10-18

Similar Documents

Publication Publication Date Title
ATE346303T1 (de) Mit alzheimer krankheit verknüpften verfahren zur diagnose, zur herstellung von medikamenten und zum screenen von substanzen sowie aus beta- amyloid abgeleiteten peptiden
ATE364623T1 (de) Peptid zur diagnose und therapie der alzheimer- demenz
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
DE69833755D1 (de) Verfahren zur herstellung von nicht-immunogenen proteinen
DK0751992T3 (da) Karendotelvækstfaktor 2
ATE244018T1 (de) Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer
IL124728A0 (en) Diagnosis and treatment of aur-1 and/or aur-2 related disorders
ATE510552T1 (de) Verfahren zur herstellung von sekretierte verkurzte varianten des humanen thyrotropinrezeptors
ATE123780T1 (de) Verfahren zur verwendung und herstellung von peptiden.
EP0762885A4 (en) Glial mitogenic factors, their preparation and use
EP1361229A3 (en) Use of Tyrosine Kinase (PYK2) to produce antibodies
DE69633717D1 (de) Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
ATE213836T1 (de) Verfahren zur herstellung von diagnostischen reagentien, testverfahren und medikamenten, die auf den klinischen manifestationen einer krankheit beruhen
DE3782440D1 (de) Verfahren und ausruestung zur herstellung von radioaktivmarkierten antikoerpern fuer die in-vivo-krebsdiagnose und therapie.
EP0538401A4 (en) Novel receptor-type phosphotyrosine phosphatase
WO1995005604A3 (en) Methods for the diagnosis of alzheimer's disease
DE3880082D1 (de) Verfahren zur herstellung von polyimid und verbundmaterial daraus.
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
WO2000017235A3 (en) Cytokine receptor zalpha11
D’Alessio et al. Long-term development of human iPSC-derived pyramidal neurons quantified after transplantation into the neonatal mouse cortex
EP1179588A4 (en) HUMAN BRAIN-SPECIFIC CARBOXYPEPTIDASE
DE60143608D1 (de) Neueskollagen-ähnliches protein clac, dessen vorläufer und dafür kodierende gene
GEP20043386B (en) β -Amyloid Peptide-Binding Proteins and Polynucleotides Encoding the Same
ATE335759T1 (de) Verfahren und zusammensetzungen für die diagnose und die behandlung von krankheiten, die mit eisenüberschuss oder eisenmangel assoziiert sind.
DE3786673D1 (de) Verfahren zur entfernung unerwuenschter zellen aus menschlichen lymphozytenpopulationen, anwendung des verfahrens zur herstellung monoklonaler antikoerper und dafuer geeigneter kit.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties